第2章 癌治療における小分子薬の役割

第3章 小分子癌治療薬のメカニズム

第4章 小分子癌治療薬の市場概要

第5章 小分子癌治療薬の市場力学

第6章 小分子癌治療薬市場の将来見通し

第7章 小分子癌治療薬の臨床パイプライン：企業・適応・フェーズ別

第8章 上市済み小分子癌治療薬の臨床分析

第9章 競合情勢

AstraZeneca

Bayer

Boehringer Ingelheim

Cadila Pharmaceutical

Eli Lily

GalaxoSmithKline

Johnson & Johnson

Merck

Novartis

Pfizer

Roche

Sun Pharmaceuticals

図表

目次

Oncologists are continuously looking for better therapeutic options to effectively cure and prevent different types of malignancies. Conventionally, surgery and radiation were widely used for cancer treatment but they have modest benefits. Presently, global market consists of several options for cancer treatment which belongs to various classes of molecules. Their utilization in therapeutic regime depends on the patient's medical condition, pharmacological and financial benefits offered by them during treatment. Out of these classes of therapeutic molecules, small molecules have been found to have substantial impact on cancer treatment due to which they are widely accepted by oncologists and patients.

Small molecules are widely used for cancer treatment because they can easily infiltrate into the tumorous cells and prevent its proliferation. Chemotherapeutic drugs are also small molecules, generally used in cancer treatment for several decades. They are still used as first line cancer therapeutics and they have highly developed cancer market. Chemotherapeutics have helped in decreasing the mortality rates but their severe side effects cause high morbidity rates. This fact made the researchers to search for other small molecules which can provide better pharmacological effects with minimized side effects in cancer patients. As a result, after several decades of research newer small molecules belonging to different classes have been formulated for cancer treatment.

High versatility is another benefit offered by small molecule due to which they can be used for the treating different types of cancers. Research in this field is progressing and several molecules are under investigation for their pharmacological efficacy. Conventional therapies in cancer of sensitive tissue may have life threatening effects instead of therapeutic benefit. For instance, a newly discovered molecule called TIC10 has been found as a potential treatment against brain tumour. It is under development at laboratory phase and someday it may enter in clinical trials in coming years. Many other small molecules are under development for the treatment of Non-Small Cell Lung Cancer (NSCLC), Colon cancer, Breast and other cancers.

Development of small molecule cancer drug generally involves target identification and pharmacological efficacy provided during clinical trials. Different types of cancer have different physiological characteristics due to which effective treatment requires the small molecule showing preferential selectiveness towards a particular cell group. Technological limitations are one of the biggest hindrances in the speedy development of small molecules for cancer treatment but this is expected to be overcome with time due to increased investments in research and development segment. New small cancer drugs based on novel technology are expected to enter in global market in coming years.